NCT05309304View on ClinicalTrials.gov

Cefazolin PK Study 3g vs 2g

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

August 30, 2022

Study Completion Date

August 30, 2022

Conditions

Healthy

Interventions

DRUG

Cefazolin

Cefazolin Injection - 2 g/100 mL or 3 g/150 mL

Trial Locations (1)

21225

Baxter Investigational Site, Baltimore

All Listed Sponsors

lead

Baxter Healthcare Corporation

INDUSTRY